{"id":53147,"date":"2023-01-20T17:02:31","date_gmt":"2023-01-20T16:02:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/digital-biomarkers-market-analysis-report-2022-wearable-mobile-based-applications-sensors-global-forecast-to-2030-researchandmarkets-com\/"},"modified":"2023-01-20T17:02:31","modified_gmt":"2023-01-20T16:02:31","slug":"digital-biomarkers-market-analysis-report-2022-wearable-mobile-based-applications-sensors-global-forecast-to-2030-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/digital-biomarkers-market-analysis-report-2022-wearable-mobile-based-applications-sensors-global-forecast-to-2030-researchandmarkets-com\/","title":{"rendered":"Digital Biomarkers Market Analysis Report 2022: Wearable, Mobile based Applications, Sensors – Global Forecast to 2030 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Digital Biomarkers Market Size, Share & Trends Analysis Report by Type (Wearable, Mobile based Applications, Sensors), by Clinical Practice, by Therapeutic Area, by End-use, by Region, and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global digital biomarkers market size is expected to reach USD 13,966.16 million by 2030, registering a CAGR of 21.9%\n<\/p>\n

\nDue to the rising acceptance of recent advancements and remote technologies, the market for digital biomarkers is anticipated to expand throughout the forecast period. Development of the remote data collecting technologies, which make up the largest segment of the market for digital biomarkers, has been propelled by the improvements in wearable and mobile technology. Additionally, this market segment is being further assisted by the growing use of the internet.\n<\/p>\n

\nVocal digital biomarkers in particular have lately come into existence and offer enormous business development potential. They enable easy data collection through voice recordings and through patient-owned technology like cell phones, wearables, and other devices. Vocal biomarkers are being utilized more frequently, which might ease the strain on the healthcare systems and improve patient outcomes by enhancing early intervention and before-time identification of physical or mental illnesses, boosting the market’s expansion during the forecast period.\n<\/p>\n

\nFurthermore, in order to acquire market presence and further boost its revenue market share during the forecast, players have also begun exploring the vocal digital biomarkers. For instance, in October 2021, Sonde health launched a voice-enabled mental fitness monitoring technology platform.\n<\/p>\n

\nAdditionally, the market is anticipated to experience substantial expansion during the forecast period due to the rising prevalence of chronic diseases and neurodegenerative diseases, as well as the growing need for enhanced drug development to successfully control these diseases. In comparison to the conventional clinical trial process, digital biomarkers accelerate the development of new drugs.\n<\/p>\n

\nAccording to a study by one of the well-known decentralized trial platform providers, Med able, 85.0% of all clinical trials experience some sort of delay, with the financial impact of delays costing between USD 600,000 and USD 8 million per day, decentralized clinical trials could save up to 1 to 3 months of time in phase 2 studies.\n<\/p>\n

\nAs a result, medicine manufacturers are spending money on a digital biomarker for DCT, which is anticipated to fuel market expansion. For instance, AstraZeneca stated in March 2022 that it had invested USD 33.0 million in Huma, a UK-based company that provides decentralized clinical trials based on remote digital biomarkers. Through this alliance, the company will quicken the adoption of DCT.\n<\/p>\n

\nForward-thinking market participants are expanding their decisions and moving beyond typical suppliers in order to strengthen the company’s position in the global market for digital biomarkers by utilizing the wide range of technology capabilities and services required for future success.\n<\/p>\n

\nThese companies have employed a variety of strategies such as product launches, joint ventures, and mergers & acquisitions. For instance, in April 2022, Pfizer acquired ResApp, an Australian- based startup that had created an app that uses artificial intelligence to gauge and determine the severity of respiratory problems using the coughing voice of a patient.\n<\/p>\n

\nDigital Biomarkers Market Report Highlights<\/strong>\n<\/p>\n